WALTHAM,
Mass., May 9, 2024 /PRNewswire/ -- Syndax
Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical
company developing an innovative pipeline of cancer therapies,
today announced that members of the Syndax management team will
participate in a fireside chat at the Bank of America Securities
2024 Health Care Conference on Thursday, May
16, 2024, at 8:00 a.m. PT/
11:00 a.m. ET.
A live webcast of the fireside chat can be accessed from the
Investor section of the Company's website at www.syndax.com, where
a replay of the event will also be available for a limited
time.
About Syndax
Syndax Pharmaceuticals is a clinical stage
biopharmaceutical company developing an innovative pipeline of
cancer therapies. Highlights of the Company's pipeline include
revumenib, a highly selective menin inhibitor, and axatilimab, a
monoclonal antibody that blocks the colony stimulating factor 1
(CSF-1) receptor. For more information, please visit. For more
information, please visit www.syndax.com or follow the
Company on X (formerly Twitter) and LinkedIn.
Syndax Contact
Sharon
Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
SNDX-G
View original
content:https://www.prnewswire.com/news-releases/syndax-announces-participation-at-the-bank-of-america-securities-2024-health-care-conference-302140895.html
SOURCE Syndax Pharmaceuticals, Inc.
